In December 2009 a novel metallo-b-lactamase was identified in a patient hospitalized in New Delhi with an infection caused by klebsiella pneumonia [4] . This b-lactamase was later detected in bacteria in India, Pakistan, United Kingdom, United States, and Canada. The New Delhi metallo-b-lactamase (NDM-1) has the ability to make bacteria resistant to a wide range of b-lactam antibiotics, including the carbapenem family antibiotics that are a mainstay for the treatment of antibiotic-resistant bacterial infections [5, 6] . According to the report of the United Kingdom's Health Protection Agency, most isolates with NDM-1 are resistant to all standard intravenous antibiotics for the treatment of severe infections. The most common bacteria that make this enzyme are Gram negative such as Escherichia coli and Klebsiella pneumonia, but the gene for NDM-1 can spread from one strain of bacteria to another by horizontal gene transfer.